A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event (NCT07000357)
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.
Who can join: Review the eligibility criteria below.
Location: Research Site — Athens, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1452 Sites)
Showing the first 25 of 1452 sites.
- Research Site — Athens, Alabama
- Research Site — Birmingham, Alabama
- Research Site — Birmingham, Alabama
- Research Site — Fairhope, Alabama
- Research Site — Foley, Alabama
- Research Site — Huntsville, Alabama
- Research Site — Huntsville, Alabama
- Research Site — Irondale, Alabama
- Research Site — Mobile, Alabama
- Research Site — Northport, Alabama
- Research Site — Saraland, Alabama
- Research Site — Vestavia Hills, Alabama
- Research Site — Gilbert, Arizona
- Research Site — Gilbert, Arizona
- Research Site — Glendale, Arizona
- Research Site — Mesa, Arizona
- Research Site — Peoria, Arizona
- Research Site — Phoenix, Arizona
- Research Site — Phoenix, Arizona
- Research Site — Phoenix, Arizona
- Research Site — Phoenix, Arizona
- Research Site — Scottsdale, Arizona
- Research Site — Tempe, Arizona
- Research Site — Tucson, Arizona
- Research Site — Tucson, Arizona
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cardiovascular Disease
- Genes, Omega-3 Fatty Acids and Cardiovascular Disease Risk Factors — Québec,
- Hispanic Community Health Study / Study of Latinos — Chapel Hill, North Carolina
- EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction — Birmingham, Alabama
- Nitric Oxide Bioavailability and Early Life Stress (NO-Stress) — Augusta, Georgia
- Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease — Houston, Texas
- Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction — Los Angeles, California
Explore by condition: All Cardiovascular Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.